The extended deal with DSM offers Aerie an elite worldwide license to DSM’s polyesteramide polymer technology for a limitless number of drugs in any ophthalmic indication and also an exposure to DSM’s preclinical latanoprost implant created for people with glaucoma. The two companies have spanned their partnership till the end of 2020, as per Aerie.
Glaucoma is an eye disorder causing irreversible blindness and affects around 60 million people throughout the world. This condition leads to the loss of retinal ganglion cells, located near the surface of the retina. The prime focus of glaucoma research is to put an end to the loss of these cells in the initial stages.
Vision scientists at the University of California, Berkeley, and the University of Toronto have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma, the world's second-leading cause of blindness.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.